Kurma Partners. (5/2/24). "Press Release: Kurma Partners Announces the Promotion of Hadrien Bouchez to the Position of Partner". Paris.

	Organisation	Kurma Biofund
	Group	Eurazeo (Group)
	Organisation 2	Emergence Therapeutics AG
	Group	Eli Lilly (Group)
	Product	venture capital
	Product 2	BIOTECH
	Person	Bouchez, Hadrien (Kurma Partners 202011– promoted to Principal from Associate joined 2014 as Analyst)
	Person 2	Droller, Rémi (Kurma 201305 Managing Partner at Kurma Life Sciences Partners)

Kurma Partners announces the promotion of Hadrien Bouchez to the position of Partner acknowledging his valuable contribution to the development of the firm.

Hadrien, who joined Kurma Partners in 2014 as an Analyst, has played a significant role in building the firm’s Biofund strategy which has a strong focus on company creation and investments. In particular, Hadrien was involved in investments in Emergence Therapeutics, Pharvaris, Corlieve Therapeutics, Flamingo Therapeutics, Amolyt Pharmaceuticals and Ermium Therapeutics.

In his new role, Hadrien will be responsible for making and managing investments in the Biofund team.

"We are delighted to announce the well-deserved promotion of Hadrien Bouchez to Partner position, recognizing his contribution and commitment since joining our firm in 2014," said Rémi Droller, Managing Partner, “The expansion of the partnership with Hadrien marks the growth and strengthening of our Biofund franchise” added Thierry Laugel, Managing Partner.

Hadrien Bouchez added: “I am deeply honored by the promotion to Partner and very excited to continue working with this fantastic team, building and investing in biotech companies developing innovative therapies to impact the lives of patients and their families.”

Hadrien holds a PharmD from the Faculty of Pharmacy, Lille, and a Master in Entrepreneurship from the ESSEC Business School.

About Kurma Partners

Founded in 2009 in Paris, Kurma Partners has become a key player in Europe, financing innovation to build the healthcare industry of tomorrow. Kurma invests from company formation to growth capital, in particular through its funds Kurma Biofund, Kurma Growth Opportunities and Kurma Diagnostics. Kurma’s teams based in Paris and Munich, are embedded within the European ecosystem and have strong international networks spanning prestigious research institutes and hospitals, entrepreneurs, industry and investors.

More information on www.kurmapartners.com

Record changed: 2024-06-05